Loading...
•
Sep 30, 2022
Alnylam Q3 2022 Earnings Report
Alnylam reported strong Q3 2022 results driven by commercial and clinical execution, with AMVUTTRA's successful U.S. launch and positive clinical trial outcomes.
Key Takeaways
Alnylam Pharmaceuticals reported strong third-quarter results, highlighted by $232 million in global net product revenues, driven by ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. AMVUTTRA's U.S. launch contributed significantly to growth. The company is on track to submit an sNDA for ONPATTRO and anticipates several pipeline milestones.
Global net product revenues reached $232 million, driven by ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO.
AMVUTTRA's first full quarter in the U.S. achieved $25 million in net product revenues.
The U.S. market experienced 30% total TTR growth, bolstered by the AMVUTTRA launch.
Positive results from the APOLLO-B Phase 3 study of Patisiran were reported, with an sNDA submission on track for late 2022.
Revenue by Segment
Forward Guidance
Alnylam reaffirmed its full-year 2022 combined net product revenue guidance of $870 million to $930 million. The net revenues from collaborations and royalties guidance was updated to $100 million - $150 million. The GAAP and Non-GAAP R&D and SG&A expenses guidance remain unchanged.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...